Details of the Drug Combinations

General Information of This Drug (ID: DMF98Q0)

• Drug Name: Momelotinib (DMF98Q0)
• Synonyms: Cyt387; 1056634-68-4; MOMELOTINIB; Cyt-387; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)amino)pyrimidin-4-yl)benzamide; CYT 387; CYT 11387; UNII-6O01GMS00P; N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide; 6O01GMS00P; CHEMBL1078178; AK102858; N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide; N-(cyanomethyl)-4-(2-{[4-(morpholin-4-yl)phenyl]amino}pyrimidin-4-yl)benzamide; CYT387 sulfate salt; N-(Cyanomethyl)-4-(2-((4-morpholinophenyl)-amino)pyrimidin-4-yl)benzamide

Indication

Myelofibrosis; ICD 11: 2A20.2; Status: Approved [1]; Polycythemia vera; ICD 11: 2A20.4; Status: Phase 2 [2]; Thrombocythemia; ICD 11: 3B63; Status: Phase 2 [2]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

1 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Momelotinib + Mitomycin	DCOMYRD	Mitomycin	Diffuse large B cell lymphoma (Cell Line: TMD8)	[3]

4 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Erlotinib + Momelotinib	DCWDWWK	Erlotinib	EGFR Mutated EGFR TKI Naive Metastatic NSCLC	[4]
Momelotinib + Oxaliplatin	DCB58IY	Oxaliplatin	Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma	[5]
Momelotinib + Capecitabine	DCV1EC5	Capecitabine	Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma	[5]
Trametinib + Momelotinib	DCZMV46	Trametinib	Relapsed Metastatic KRAS-Mutated Non-Small Cell Lung Cancer	[6]

References

• [1] FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 216873
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [4] ClinicalTrials.gov (NCT02206763) Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)
• [5] ClinicalTrials.gov (NCT02244489) Momelotinib Combined With Capecitabine and Oxaliplatin in Adults With Relapsed/Refractory Metastatic Pancreatic Ductal Adenocarcinoma
• [6] ClinicalTrials.gov (NCT02258607) Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase